Last reviewed · How we verify
leuprorelin acetate 3.75mg
Leuprorelin acetate 3.75mg, marketed by Peptron, Inc., holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | leuprorelin acetate 3.75mg |
|---|---|
| Also known as | PT105 |
| Sponsor | Peptron, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (PHASE2)
- Rezvilutamide for High-Risk Prostate Cancer After Surgery (NA)
- RWE About QOL and Compliance of Patients With OFS in China
- Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (PHASE2)
- PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate (PHASE2)
- Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine (PHASE4)
- Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer (PHASE2)
- Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- leuprorelin acetate 3.75mg CI brief — competitive landscape report
- leuprorelin acetate 3.75mg updates RSS · CI watch RSS
- Peptron, Inc. portfolio CI